The Ebola species with no vaccine, Pg10

Key Highlights:

• The WHO declared the Bundibugyo ebolavirus (BDBV) outbreak in DRC and Uganda a Public Health Emergency of International Concern on May 17.
• There is currently no licensed vaccine for the Bundibugyo species of ebolavirus due to lack of resources and economic factors associated with Neglected Tropical Diseases (NTDs).
• Promising Bundibugyo vaccine candidates are in preclinical or early development, with potential for small clinical trials in at least six months.
• Local healthcare systems are focusing on detecting cases, isolating patients, contact-tracing, safe burial practices, and community engagement to manage the outbreak.

Detailed Insights:

• The ebolavirus genus includes species like Zaire, Sudan, Bundibugyo, and Taï Forest, with immunity to one species not guaranteeing protection against others due to differing surface proteins.
• Developing ebolavirus vaccines requires identifying viral proteins that provoke antibody responses, selecting a platform like viral vectors or mRNA, and testing in animal models, particularly non-human primates.
• Manufacturing vaccines requires significant investment, specialized facilities, cold storage, quality control, regulatory approvals, and advance purchase commitments, making it challenging for diseases primarily affecting lower-income countries.
• Initiatives like the London Declaration and Kigali Declaration have aimed to address NTDs through funding commitments, but research and development remain patchy due to weak healthcare delivery and disease surveillance.
• The African Union's 'ACHIEVE Africa' program aims to build indigenous R&D for vaccine development for NTDs, with a goal to manufacture 60% of the continent’s vaccine needs by 2040.

Key Concepts Involved:

• Neglected Tropical Diseases (NTDs): Diseases affecting poor, rural, and politically marginalized populations in tropical and subtropical areas.
• Biosafety Level (BSL) 4 facilities: Research facilities with the highest level of biological containment for working with deadly viruses.
• Viral Vectors: Tools used to deliver genetic material into cells, often used in vaccine development to present antigens to the immune system.